We then identified the novel molecular mechanisms by which sHTG caused by ApoA5 deficiency in hamsters elicited NAFLD and explored the potential therapeutic approaches to treat sHTG-related disorders. The gene discussed is APOA5; the disease is metabolic dysfunction-associated steatotic liver disease.